RYTM FY2027 EPS Estimate Lifted by Needham & Company LLC

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at Needham & Company LLC lifted their FY2027 earnings per share estimates for shares of Rhythm Pharmaceuticals in a note issued to investors on Monday, April 14th. Needham & Company LLC analyst J. Stringer now forecasts that the company will post earnings of $1.43 per share for the year, up from their previous estimate of $1.42. Needham & Company LLC has a "Buy" rating and a $66.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million during the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%.

RYTM has been the topic of a number of other research reports. Morgan Stanley restated an "overweight" rating and set a $72.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They issued a "buy" rating and a $78.00 price target for the company. Jefferies Financial Group assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a "buy" rating and a $80.00 target price on the stock. Canaccord Genuity Group lifted their price target on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Finally, Wells Fargo & Company increased their target price on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a research note on Monday, April 7th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $74.92.

Rhythm Pharmaceuticals Price Performance

RYTM stock traded up $0.49 during trading on Wednesday, reaching $62.23. 163,264 shares of the stock traded hands, compared to its average volume of 541,204. The business's 50 day moving average price is $54.79 and its 200-day moving average price is $55.73. The firm has a market capitalization of $3.93 billion, a PE ratio of -14.37 and a beta of 2.32. Rhythm Pharmaceuticals has a 52-week low of $35.17 and a 52-week high of $68.58.

Insider Transactions at Rhythm Pharmaceuticals

In related news, EVP Yann Mazabraud sold 75,000 shares of Rhythm Pharmaceuticals stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $51.48, for a total value of $3,861,000.00. Following the transaction, the executive vice president now owns 40,370 shares of the company's stock, valued at approximately $2,078,247.60. This trade represents a 65.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Christopher Paul German sold 635 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total transaction of $36,334.70. Following the completion of the transaction, the chief accounting officer now owns 2,070 shares of the company's stock, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 146,641 shares of company stock valued at $8,112,177 in the last three months. 5.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RYTM. Assenagon Asset Management S.A. acquired a new stake in shares of Rhythm Pharmaceuticals during the first quarter worth approximately $1,176,000. SG Americas Securities LLC purchased a new position in shares of Rhythm Pharmaceuticals during the 1st quarter valued at $1,042,000. Harbor Capital Advisors Inc. increased its stake in shares of Rhythm Pharmaceuticals by 155.5% in the first quarter. Harbor Capital Advisors Inc. now owns 77,297 shares of the company's stock worth $4,094,000 after acquiring an additional 47,045 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Rhythm Pharmaceuticals by 3.6% during the first quarter. Rhumbline Advisers now owns 85,719 shares of the company's stock worth $4,541,000 after acquiring an additional 2,988 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Rhythm Pharmaceuticals by 7,305.5% in the 1st quarter. GAMMA Investing LLC now owns 14,885 shares of the company's stock worth $788,000 after purchasing an additional 14,684 shares during the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.